Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) EBT (2020 - 2025)

Historic EBT for iSpecimen (ISPC) over the last 6 years, with Q3 2025 value amounting to -$2.8 million.

  • iSpecimen's EBT fell 6534.49% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.3 million, marking a year-over-year decrease of 2674.53%. This contributed to the annual value of -$12.9 million for FY2024, which is 1855.21% down from last year.
  • According to the latest figures from Q3 2025, iSpecimen's EBT is -$2.8 million, which was down 6534.49% from -$1.8 million recorded in Q2 2025.
  • iSpecimen's 5-year EBT high stood at -$1.4 million for Q2 2021, and its period low was -$6.0 million during Q4 2024.
  • For the 5-year period, iSpecimen's EBT averaged around -$2.5 million, with its median value being -$2.2 million (2024).
  • Its EBT has fluctuated over the past 5 years, first plummeted by 70058.43% in 2021, then soared by 4494.69% in 2025.
  • iSpecimen's EBT (Quarter) stood at -$2.0 million in 2021, then dropped by 6.51% to -$2.2 million in 2022, then plummeted by 30.96% to -$2.8 million in 2023, then plummeted by 111.96% to -$6.0 million in 2024, then soared by 52.79% to -$2.8 million in 2025.
  • Its EBT was -$2.8 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$1.6 million in Q1 2025.